Related references
Note: Only part of the references are listed.MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma
Masoud Sotoudeh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
Ruocong Zhao et al.
ONCOIMMUNOLOGY (2019)
Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy
Y. Huang et al.
GENE THERAPY (2018)
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Y. Lai et al.
LEUKEMIA (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
Jiayi Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy
John C. Hardaway et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
Driving gene-engineered T cell immunotherapy of cancer
Laura A. Johnson et al.
CELL RESEARCH (2017)
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Clinical trials of CAR-T cells in China
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu et al.
CELL REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Giedre Krenciute et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Incorporation of functional elements enhances the antitumor capacity of CAR T cells
Le Qin et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeted therapy for gastric cancer: Current status and future directions
Dan-Dan Yuan et al.
ONCOLOGY REPORTS (2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
S. C. Katz et al.
CANCER GENE THERAPY (2016)
Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis
Jing Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Gregory L. Beatty et al.
PHARMACOLOGY & THERAPEUTICS (2016)
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
Qi Zhang et al.
ONCOIMMUNOLOGY (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells
Yiren Xiao et al.
HAEMATOLOGICA (2015)
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
Hinrich Abken
IMMUNOTHERAPY (2015)
Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments
Wei Ye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells
Yiren Xiao et al.
HAEMATOLOGICA (2015)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (vol 2, pg 112, 2014)
G. L. Beatty
CANCER IMMUNOLOGY RESEARCH (2015)
Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention
Parisa Karimi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
CAR T Cells for Solid Tumors Armed and Ready to Go?
Sunitha Kakarla et al.
CANCER JOURNAL (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
Tomoaki Ito et al.
ONCOLOGY REPORTS (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
Cecilia Duraes et al.
VIRCHOWS ARCHIV (2014)
Treatment of gastric cancer
Michele Orditura et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Novel targeted agents for gastric cancer
Lian Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
De-Gang Song et al.
CANCER RESEARCH (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Yangbing Zhao et al.
CANCER RESEARCH (2010)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
Xiao-Song Zhong et al.
MOLECULAR THERAPY (2010)